Tempus AI is trading 5.5% up now at $70.33 after investors continued rewarding its $1.5 billion Personalis acquisition, whose genomic technology supports Moderna’s personalized cancer-vaccine program. Moderna’s positive Phase 3 results strengthened confidence in the deal’s strategic value.
- Trading at $70.33 (+5.52%)
- Rally extends after gains of 24.09% on August 19 and 8.82% on August 20.
- The broader market is modestly higher, but company-specific deal optimism appears dominant. Confidence: Medium, based on aligned financial-news coverage.